These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27276518)

  • 1. Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine.
    Akazawa T; Uchida Y; Tachikawa M; Ohtsuki S; Terasaki T
    Mol Pharm; 2016 Jul; 13(7):2443-56. PubMed ID: 27276518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.
    Stephens RH; Tanianis-Hughes J; Higgs NB; Humphrey M; Warhurst G
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1095-101. PubMed ID: 12438532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
    Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
    Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.
    Jin M; Shimada T; Yokogawa K; Nomura M; Ishizaki J; Piao Y; Kato Y; Tsuji A; Miyamoto K
    Biochem Pharmacol; 2006 Oct; 72(8):1042-50. PubMed ID: 16939683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
    Uchida Y; Ohtsuki S; Terasaki T
    Drug Metab Dispos; 2014 Oct; 42(10):1719-26. PubMed ID: 25061162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.
    Jin M; Shimada T; Yokogawa K; Nomura M; Kato Y; Tsuji A; Miyamoto K
    Int J Pharm; 2006 Feb; 309(1-2):81-6. PubMed ID: 16384676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.
    Miyauchi E; Tachikawa M; Declèves X; Uchida Y; Bouillot JL; Poitou C; Oppert JM; Mouly S; Bergmann JF; Terasaki T; Scherrmann JM; Lloret-Linares C
    Mol Pharm; 2016 Aug; 13(8):2631-40. PubMed ID: 27347605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
    Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
    Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport.
    Sadiq MW; Uchida Y; Hoshi Y; Tachikawa M; Terasaki T; Hammarlund-Udenaes M
    PLoS One; 2015; 10(5):e0118638. PubMed ID: 25932627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
    Nakanishi H; Yonezawa A; Matsubara K; Yano I
    Eur J Pharmacol; 2013 Jun; 710(1-3):20-8. PubMed ID: 23588114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
    Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
    Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics.
    Zamek-Gliszczynski MJ; Goldstein KM; Paulman A; Baker TK; Ryan TP
    Drug Metab Dispos; 2013 Jun; 41(6):1174-8. PubMed ID: 23569176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.
    Varma MV; Panchagnula R
    J Pharm Sci; 2005 Dec; 94(12):2632-43. PubMed ID: 16258992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.
    Makhey VD; Guo A; Norris DA; Hu P; Yan J; Sinko PJ
    Pharm Res; 1998 Aug; 15(8):1160-7. PubMed ID: 9706044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells.
    Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G;
    Drug Metab Dispos; 2016 Mar; 44(3):297-307. PubMed ID: 26631742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.